Oppenheimer & Co. Inc. significantly increased its stake in Biogen Inc. by 501.1% in Q3, now holding 13,610 shares valued at approximately $1.91 million. The firm has also raised its price target for Biogen to $225 with an “outperform” rating. Biogen recently exceeded quarterly earnings expectations with an EPS of $1.99 and revenue of $2.28 billion, and has provided strong FY2026 guidance.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Oppenheimer & Co. Inc. Has $1.91 Million Stock Position in Biogen Inc. $BIIB
Oppenheimer & Co. Inc. significantly increased its stake in Biogen Inc. by 501.1% in Q3, now holding 13,610 shares valued at approximately $1.91 million. The firm has also raised its price target for Biogen to $225 with an “outperform” rating. Biogen recently exceeded quarterly earnings expectations with an EPS of $1.99 and revenue of $2.28 billion, and has provided strong FY2026 guidance.